Please use this identifier to cite or link to this item: https://doi.org/10.1093/infdis/jir347
DC FieldValue
dc.titleKunjin virus replicon-based vaccines expressing Ebola virus glycoprotein GP protect the guinea pig against lethal Ebola virus infection
dc.contributor.authorReynard, O.
dc.contributor.authorMokhonov, V.
dc.contributor.authorMokhonova, E.
dc.contributor.authorLeung, J.
dc.contributor.authorPage, A.
dc.contributor.authorMateo, M.
dc.contributor.authorPyankova, O.
dc.contributor.authorGeorges-Courbot, M.C.
dc.contributor.authorRaoul, H.
dc.contributor.authorKhromykh, A.A.
dc.contributor.authorVolchkov, V.E.
dc.date.accessioned2016-09-06T08:19:29Z
dc.date.available2016-09-06T08:19:29Z
dc.date.issued2011-11-01
dc.identifier.citationReynard, O., Mokhonov, V., Mokhonova, E., Leung, J., Page, A., Mateo, M., Pyankova, O., Georges-Courbot, M.C., Raoul, H., Khromykh, A.A., Volchkov, V.E. (2011-11-01). Kunjin virus replicon-based vaccines expressing Ebola virus glycoprotein GP protect the guinea pig against lethal Ebola virus infection. Journal of Infectious Diseases 204 (SUPPL. 3) : S1060-S1065. ScholarBank@NUS Repository. https://doi.org/10.1093/infdis/jir347
dc.identifier.issn00221899
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/126757
dc.description.abstractPre- or postexposure treatments against the filoviral hemorrhagic fevers are currently not available for human use. We evaluated, in a guinea pig model, the immunogenic potential of Kunjin virus (KUN)-derived replicons as a vaccine candidate against Ebola virus (EBOV). Virus like particles (VLPs) containing KUN replicons expressing EBOV wild-type glycoprotein GP, membrane anchor-truncated GP (GP/Ctr), and mutated GP (D637L) with enhanced shedding capacity were generated and assayed for their protective efficacy. Immunization with KUN VLPs expressing full-length wild-type and D637L-mutated GPs but not membrane anchor-truncated GP induced dose-dependent protection against a challenge of a lethal dose of recombinant guinea pig-adapted EBOV. The surviving animals showed complete clearance of the virus. Our results demonstrate the potential for KUN replicon vectors as vaccine candidates against EBOV infection. © 2011 The Author Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved.
dc.sourceScopus
dc.typeConference Paper
dc.contributor.departmentMICROBIOLOGY
dc.description.doi10.1093/infdis/jir347
dc.description.sourcetitleJournal of Infectious Diseases
dc.description.volume204
dc.description.issueSUPPL. 3
dc.description.pageS1060-S1065
dc.description.codenJIDIA
dc.identifier.isiut000295991400042
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

33
checked on May 17, 2022

WEB OF SCIENCETM
Citations

32
checked on May 17, 2022

Page view(s)

109
checked on May 12, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.